Research Paper Volume 15, Issue 21 pp 12369—12387
CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers
Figure 3. Validation of prognostic implications of CCL19 expression for PFS in BRCA patients across independent cohorts. With 4929 BRCA samples in total, PFS analysis of independent cohorts was performed.